Hyusetan Tablet (Sevelamer Carbonate)

Adult dose

This medicine should be taken with meals 3 times daily. 1) Administration to patients not taking phosphate binders The recommended initial dose of this medicine is 0.8g to 1.6g. Take 2~4 tablets of this medicine with each meal according to the serum phosphorus level, as follows. 5.5 - 7.5 ㎎/dL: Take 2 tablets per dose with meals 3 times daily 7.5 ㎎/dL or higher: Take 4 tablets per dose with meals 3 times daily 2) Substitution of this medicine for patients taking sevelamer hydrochloride tablets When substituting this medicine for sevelamer hydrochloride tablets, administer the same dose. Appropriate dose adjustment may be required to achieve the target serum phosphorus level. The maximum daily dose of sevelamer carbonate studied in patients with chronic kidney disease undergoing dialysis was 14g. 3) Substitution of this medicine for patients taking calcium acetate preparations 1 tablet per dose, 3 times daily → 2 tablets per dose, 3 times daily 2 tablets per dose, 3 times daily → 4 tablets per dose, 3 times daily 3 tablets per dose, 3 times daily → 6 tablets per dose, 3 times daily 4) Switching from sevelamer carbonate tablets to powder or from powder to tablets When switching between sevelamer carbonate tablets and powder, administer the same dose. Appropriate dose adjustment may be required to achieve the target serum phosphorus level. 5) Dose adjustment in all patients taking this medicine If necessary, increase or decrease the dose of this medicine by 0.8g, at 2-week intervals, with meals 3 times daily until the target serum phosphorus level is achieved.

This medication should not be used in patients who are hypersensitive to the active ingredient or excipients. It should also not be used in patients with hypophosphatemia or intestinal obstruction. Caution is required for patients with intestinal strictures or severe constipation, as this medication can swell in the gastrointestinal tract and may lead to obstruction or perforation. During treatment, gastrointestinal adverse reactions such as vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation may occur, and care should be taken. Patients undergoing peritoneal dialysis are at risk for peritonitis, so symptoms of peritonitis should be monitored immediately and appropriate treatment received. This medication does not contain calcium or alkaline components, so calcium and bicarbonate levels in the blood should be checked regularly, and calcium supplements taken if necessary. Long-term use may lead to deficiencies of fat-soluble vitamins (A, D, E, K) and folic acid, thus regular blood tests are necessary, and vitamin supplements should be taken if needed. Patients with dysphagia may find it difficult to swallow this medication, so a powdered form should be considered. When taken with other oral medications, it may affect the absorption of those drugs, so it is advisable to take this medication at least 1 hour before or after other medications. Pregnant women should use this medication cautiously, considering its effects on the fetus, while breastfeeding women should consult a healthcare professional since it is unlikely to be secreted in breast milk. The safety and efficacy of this medication in children under 18 years of age have not been established. There is no specific report of overdose, but the recommended dosage should be followed. This medication must be taken with food and should not be crushed or chewed but swallowed whole, and stored away from moisture. If symptoms of severe constipation, persistent abdominal pain, or vomiting occur during use, the medication should be stopped immediately and a doctor consulted. No studies have been conducted on its effects on driving or operating machinery, so caution is advised.

• Vomiting
• nausea
• diarrhea
• indigestion
• abdominal pain
• bloating
• constipation
• peritonitis
• hypersensitivity
• itching

This medication can be sensitive to air or moisture, so it should be stored in a tightly closed container. The storage temperature should be maintained between 1 and 30 degrees Celsius to ensure the safety and effectiveness of the medication.

Appearance

White or grayish oval film-coated tablets

Package unit

30 tablets/bottle, 360 tablets/bottle